In an Aug. 11 op-ed on the North Carolina Biotechnology Center website, UNC Vice Chancellor for Research Penny Gordon-Larsen described the current research landscape as full of opportunities and potholes, in part because of the rise of AI.
“In this rapidly evolving sector, leadership will be defined by the ability to cultivate exceptional talent and navigate systemic constraints to connect research, capital and translation [of research into treatments and cures],” she wrote. “This is not possible without a steadfast commitment from our partners in the federal government and private industry.”
But such a commitment, she said, is not a given. Venture capital investment for biotech research is at a five-year low. Federal funding is fraught with its own uncertainties, from executive branch budget pressures and shifting agency priorities to the continuing battle over so-called “indirect costs” incurred by large research universities, including Carolina.
“These barriers have slowed the innovation pipeline and led to talent leakage from universities to the private sector or overseas,” Gordon-Larsen wrote. “The risks are greatest for regions like ours, which have been the beneficiaries of a rich research ecosystem that has historically driven economic development.”
Enter artificial intelligence, which depends largely on innovative humans who develop the technologies and scientists who use them for biomedical research.
“AI has only just begun to reshape the drug discovery landscape,” she wrote, “but it is doing so in a landscape rife with volatility, skepticism and shifting expectations.”
She said federal funding is critical for AI-driven discovery, validating early ideas and experiments and creating powerful databases and platforms that make biotech commercialization possible. Moreover, she wrote, federal investment helps academic researchers and administrators attract venture capital and pharmaceutical partners.
“When we get this right,” she wrote, “amazing things happen.”
Gordon-Larsen pointed to the example of Jude Samulski, a professor at Carolina who parlayed decades of federal investment in gene therapy research into a biotech company he founded to create treatments and cures for rare diseases. The company also translated into hundreds of jobs.
“Universities are workforce engines, startup incubators and regional economic anchors,” Gordon-Larsen wrote, “with every federal dollar translating to substantial downstream economic development.”
In fiscal year 2025, UNC research alone supported 24,087 jobs and contributed $2.9 billion to the state’s GDP. According to United for Medical Research, a nonprofit that advocates for sustained federal research support, UNC’s $514 million in 2025 NIH funding has had a $1.32 billion impact on the state’s economy and created nearly 5,000 jobs.
Penny Gordon-Larsen is on the board of directors of the N.C. Biotechnology Center, which is dedicated to accelerating innovation, investment and job creation in the life sciences across the state. Her full op-ed is available on its website.